The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Uskach T.M.

Empagliflozin as a part of optimal medical therapy for chronic heart failure

Authors:

Uskach T.M.

More about the authors

Journal: Russian Cardiology Bulletin. 2022;17(2): 16‑24

DOI: 10.17116/Cardiobulletin20221702116

Read: 11780 times

Download PDF (RU)
Contact the author
Table of contents

EMPAGLIFLOZIN AS A PART OF OPTIMAL MEDICAL THERAPY FOR CHRONIC HEART FAILURE
EMPAGLIFLOZIN AS A PART OF OPTIMAL MEDICAL THERAPY FOR CHRONIC HEART FAILURE

To cite this article:

Uskach TM. Empagliflozin as a part of optimal medical therapy for chronic heart failure. Russian Cardiology Bulletin. 2022;17(2):16‑24. (In Russ.)
https://doi.org/10.17116/Cardiobulletin20221702116

Подписка 2026 Кардиологический вестник (Russian Cardiology Bulletin)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Visceral obesity is a reve­rsible factor in pathogenesis of major cardiovascular diseases. Russian Cardiology Bulletin. 2025;(3):11-16
Moni­toring of chro­nic heart failure using transthoracic impe­dance and heart rate variability sensor in patients with cardioverter defi­brillator. Russian Cardiology Bulletin. 2025;(4):48-55
Intravascular physiology and imaging in dete­rmining the indi­cations for reva­scularization in patients with inte­rmediate coro­nary stenosis. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(3):255-260
Transapical myectomy in a child with hype­rtrophic cardiomyopathy. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(3):357-362
Opti­mal cardioplegia for coro­nary artery bypass grafting in patients with heart failure: a randomized study. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(4):405-411
Clinical characteristics of patients hospitalized in the Fede­ral Medi­cal Research Center. Russian Journal of Preventive Medi­cine. 2025;(8):20-26
Cardiogenic deme­ntia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):43-49
Digi­tal technologies for outpatient mana­gement of patients with chro­nic obstructive pulmonary disease: oppo­rtunities to reduce the burden of the disease. Russian Journal of Preventive Medi­cine. 2025;(9):134-139
Characteristics of surgical and drug therapy for cardiac patients hospitalized in the Fede­ral Medi­cal Research Center. Russian Journal of Preventive Medi­cine. 2026;(1):20-27
Risk-based approach as an opti­mal patients with chro­nic heart failure and cardiac rhythm diso­rders mana­gement stra­tegy. Russian Journal of Preventive Medi­cine. 2026;(3):29-34
Abstract:

This review is devoted to the role of sodium-glucose cotransporter type 2 (SGLT2) inhibitor empagliflozin in the treatment of chronic heart failure (CHF) with reduced left ventricular ejection fraction affecting the prognosis of disease. The results of clinical studies and additional analyses regarding the use of empagliflozin in various clinical situations are presented. Safety and laboratory changes following empagliflozin therapy are described. The author discusses the impact of empagliflozin on efficacy of other drugs for the treatment of CHF. Sequence of optimal medical therapy in CHF and advantages of early prescription of empagliflozin are also considered.

Keywords:

heart failure
empagliflozin
admission
renal function
optimal drug therapy

Authors:

Uskach T.M.

Received:

16.03.2022

Accepted:

01.04.2022

Close metadata

References:

  1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine. 2015;373:2117-2128. https://doi.org/10.1056/NEJMc1600827
  2. Neal B, Perkovic V, Mahaffey KW, Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthewset DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. New England Journal of Medicine. 2017;377:644-657.  https://doi.org/10.1056/NEJMoa1611925
  3. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder UF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding DPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine. 2019; 380:347-357.  https://doi.org/10.1056/NEJMoa1812389
  4. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu P-L, ZeeuwD, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. New England Journal of Medicine. 2019;380:2295-2306. https://doi.org/10.1056/NEJMoa1811744
  5. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHT, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31-39.  https://doi.org/10.1016/S0140-6736(18)32590-X
  6. Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, Mahaffey KW, Charytan DM, Wheeler DC, Arnott C, Bompoint S, Levin A, Jardine MJ. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes & Endocrinology. 2019;7:845-854.  https://doi.org/10.1016/S2213-8587(19)30256-6
  7. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi D-J, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca H-P, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde M-F, Spinar J, Squire I, Taddei S, Wanner C, Zannad F. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine. 2020;383:1413-1424. https://doi.org/10.1056/NEJMoa2022190
  8. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang SE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde A-M. DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine. 2019;381:1995-2008. https://doi.org/10.1056/NEJMoa1911303
  9. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE. EMPA-REG OUTCOME trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. European Heart Journal. 2016;37(19):1526-1534. https://doi.org/10.1093/eurheartj/ehv728
  10. Rådholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D, Fulcher G, Barrett TD, Shaw W, Desai M, Matthews DR, Neal B. Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program. Circulation. 2018;138(5):458-468.  https://doi.org/10.1161/CIRCULATIONAHA.118.034222
  11. Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019;139(22):2528-2536. https://doi.org/10.1161/CIRCULATIONAHA.119.040130
  12. Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney DZI, McGuire DK. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. New England Journal of Medicine. 2020;383(15):1425-1435. https://doi.org/10.1056/NEJMoa2004967
  13. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow SM, Greene T, Hou F-F, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström SD, Toto RD, Langkilde A-M, Wheeler DC. Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine. 2020;383(15):1436-1446. https://doi.org/10.1056/NEJMoa2024816
  14. Inzucchi SE, Zinman B, Fitchett D, Wanner C; Ferrannini E, Schumacher M, Schmoor C, Ohneberg K, Johansen OE; George JT, Hantel S, Bluhmki E, Lachin JM. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care. 2018;41:356-363.  https://doi.org/10.2337/dc17-1096
  15. Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254): 819-829.  https://doi.org/10.1016/S0140-6736(20)31824-9
  16. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Piepoli MF, Price S, Rosano GMC, Ruschitzka F, Skibelund AK. ESC Scientific Document Groupet al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42(36):3599-3726. https://doi.org/10.1093/eurheartj/ehab368
  17. Maddox TM, Januzzi JL, Larry A, Butler LAJ, Davis LL, Fonarow GC, Ibrahim, Jessup NEM, Lindenfeld JA, Maddox TM, Masoudi FA, Motiwala SR, Patterson JH, Walsh MN, Wasserman A. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology. 2021;77(6):772-810.  https://doi.org/10.1016/j.jacc.2020.11.022
  18. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709-733.  https://doi.org/10.1016/S0140-6736(20)30045-3
  19. Zannad F, Ferreira JP, Pocock SJ, Zeller C, Anker SD, Butler J, Filippatos G, Hauske SJ, Brueckmann M, Pfarr E, Schnee J, Wanner C, Packer M. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function. Circulation. 2021;26;143(4):310-321.  https://doi.org/10.1161/CIRCULATIONAHA.120.051685
  20. Packer M, Claggett B; Lefkowitz MP, McMurray JJV, Rouleau JL, Solomon SD, Zile MR. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the reninangiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes & Endocrinology. 2018;6:547-554.  https://doi.org/10.1016/S2213-8587(18)30100-1
  21. Mc Causland FR, Lefkowitz MP, Claggett B, Anavekar NS, Senni M, Gori M, Jhund PS, McGrath MM, Packer M, Shi V, Van Veldhuisen DJ, Zannad F, Comin-Colet J, Pfeffer MA, McMurray JJV, Solomon SD. Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure with Preserved Ejection Fraction. Circulation. 2020;142(13):1236-1245. https://doi.org/10.1161/CIRCULATIONAHA.120.047643
  22. Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlávek J, Böhm M, Chiang C-E, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett J, Katova T, Kitakaze M, Ljungman SEA, Merkely B, Nicolau JC, O’Meara E, Vinh PN, Schou M, Tereshchenko S, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Johanson P, Greasley PJ, Boulton D, Bengtsson O, Jhund PS, McMurray JJV. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 2020;323:1353-1368. https://doi.org/10.1001/jama.2020.1906
  23. Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C, Suda N, Siwakoti K, Ahmad T, Jacoby D, Riello R, Bellumkonda L, Cox Z, Collins S, Jeon S, Turner JM, Wilson FP, Butler J, Inzucchi SE, Testani JM. Empagliflozin in heart failure: diuretic and cardio-renal effects. Circulation. 2020;142(11):1028-1039. https://doi.org/10.1161/CIRCULATIONAHA.120.045691
  24. Packer M, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller K, George J, Brueckmann M, Anker SD, Zannad F. Evaluation of the effect of sodiumglucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. European Journal of Heart Failure. 2019;21(10):1270-1278. https://doi.org/10.1002/ejhf.1536
  25. Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, Sambevski S, Kaspers S, Pfarr E, George JT, Zinman B. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation. 2019;139:1384-1395. https://doi.org/10.1161/CIRCULATIONAHA.118.037778
  26. Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, KT Ruff, Nicolau JC, Gause-Nilsson IAM, MD, Fredriksson M, Langkilde AM, Sabatine MS, Wiviott SD. Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction. Circulation. 2019;139:2516-2527. https://doi.org/10.1161/CIRCULATIONAHA.119.039996
  27. Butler J, Anker SD, Filippatos G, Khan MS, Ferreira JP, Pocock SJ, Giannetti N, Januzzi JL, Piña IL, Lam CSP, Ponikowski P, Sattar N, Verma S, Brueckmann M, Jamal W, Vedin O, Peil B, Zeller C, Zannad F, Packer M. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. European Journal of Heart. 2021;42(13):1203-1212. https://doi.org/10.1093/eurheartj/ehaa1007
  28. Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Carson P, Anand I, Doehner W, Haass M, Komajda M, Miller A, Pehrson S, Teerlink JR, Brueckmann M, Jamal W, Zeller C, Schnaidt S, Zannad F. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction. Circulation. 2021;143(4):326-336.  https://doi.org/10.1161/CIRCULATIONAHA.120.051783
  29. Li JW, Woodward M, Perkovic V, Figtree GA, Heerspink HJL, Mahaffey KW, de Zeeuw D, Vercruysse F, Shaw W, Matthews DR, Neal B. Mediators of the effects of canagliflozin on heart failure in patients with type 2 diabetes. JACC: Heart Failure. 2020;8(1):57-66.  https://doi.org/10.1016/j.jchf.2019.08.004
  30. Packer M. Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to stimulate erythrocytosis and to alleviate cellular stress. Cardiovascular Research. 2021;117(1):74-84.  https://doi.org/10.1093/cvr/cvaa064
  31. Packer M. Uric acid is a biomarker of oxidative stress in the failing heart: lessons learned from trials with allopurinol and SGLT2 inhibitors. Journal of Cardiac Failure. 2020:S1071-9164(20)30948-30949. https://doi.org/10.1016/j.cardfail.2020.08.015
  32. Neal B, Perkovic V, Mahaffey KW. Canagliflozin and cardiovascular and renal events in type 2 diabetes. New England Journal of Medicine. 2017;377: 644-657.  https://doi.org/10.1056/NEJMc1712572
  33. Donnan JR, Grandy CA, Chibrikov E, Marra CA, Aubrey-Bassler K, Johnston K, Swab M, Hache J, Curnew D, Nguyen H, Gamble J-M. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. BMJ Open. 2019;9(1):e022577. https://doi.org/10.1136/bmjopen-2018-022577
  34. Ferreira JP, Zannad F, Pocock SJ, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Jamal W, Steubl D, Schueler E, Packer M. Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced. Journal of the American College of Cardiology. 2021;77(11):1397-1407. https://doi.org/10.1016/j.jacc.2021.01.044
  35. Desai AS, Vardeny O, Claggett B, McMurray J, Packer M, Sweberg K, Rouleau JL, Zile MR, Lefkowitz MP, Shi VC, Solomon S. Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiology. 2017;2:79-85.  https://doi.org/10.1001/jamacardio.2016.4733
  36. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. PARADIGM-HF Investigators andCommittees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine. 2014;371:993-1004. https://doi.org/10.1056/NEJMoa1409077
  37. Vaduganathan M, Claggett BL, Jhund PS Cunningham JW, Ferreira JP, Zannad F, Packer M, Fonarow GC, McMurray JJV, Solomon SD. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020;396:121-128.  https://doi.org/10.1016/S0140-6736(20)30748-0
  38. Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Brunner-La Rocca H-P, Janssens S, Tsutsui H, Zhang J, Brueckmann M, Jamal W, Cotton D, Iwata T, Schnee J, Zannad F. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal. 2021;42(6):671-680.  https://doi.org/10.1093/eurheartj/ehaa968
  39. Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz MP, Prescott MF, Shi VC, Rouleau JL, Swedberg K, Zile MR, Packer M, Desai AS, Solomon SD, McMurray JJV. Renal effects and associated outcomes during angiotensinneprilysin inhibition in heart failure. JACC Heart Failure. 2018;6:489-498.  https://doi.org/10.1016/j.jchf.2018.02.004
  40. Butler J, Zannad F, Filippatos G, Anker SD, Packer M. Totality of evidence in trials of sodium-glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice. European Heart Journal. 2020;41:3398-3401. https://doi.org/10.1093/eurheartj/ehaa731
  41. McMurray JJV, Packer M. How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction? A Redefinition of Evidence-Based Medicine. Circulation. 2021;143(9):875-877.  https://doi.org/10.1161/CIRCULATIONAHA.120.052926
  42. Anker SD, Butler J, Filippatos G, Khan MS, Marx N, Lam KSP, Schnaidt S, Ofstad AP, Brueckmann M, Jamal W, Bocchi EA, Ponikowski P, Perrone SV, Januzzi JL, Verma S, Böhm M, Ferreira JP, Pocock SJ, Zannad F, Packer M. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status — Results from the EMPEROR-Reduced Trial. Circulation. 2021;143(4):337-349.  https://doi.org/10.1161/CIRCULATIONAHA.120.051824
  43. Yasui A, Lee G, Hirase T, Kaneko T, Kaspers S, von Eynatten M, Okamura T. Empagliflozin induces transient diuresis without changing long-term overall fluid balance in Japanese patients with type 2 diabetes. Diabetes Therapy. 2018;9(2):863-871.  https://doi.org/10.1007/s13300-018-0385-5
  44. Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Sattar N, Brueckmann M, Jamal W, Cotton D, Iwata T, Zannad F. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial. Journal of the American College of Cardiology. 2021;77(11):1381-1392. https://doi.org/10.1016/j.jacc.2021.01.033
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.